Senior Marketing Manager
Michael Eder, MA, is Senior Marketing Manager at Single Use Support. He is expert in pharma and health communication with his 8+ years experience in pharma. After completing his master's degree in International Healthcare Management at MCI The Entrepreneurial school in Innsbruck, he has gained experience in the pharmaceutical field. Michael creates articles about Freeze Thaw applications and Platform solutions from Single Use Support and is the author of current news with Single Use Support worldwide.
March 22, 2022
Human errors and failures can be fatal and expensive, even more so when they occur in the medical and/or pharmaceutical fields. Single Use Support shows successful solution – learn all about them!
March 21, 2022
The aim was to achieve a freezing process where the last point of freeze always happens at the same time throughout all scales. If successful, the generated freezing curves will look very similar. Temperature ramps have been used to slow down or accelerate the freezing process.
March 21, 2022
There is no full Pharma 4.0 manufacturing in place yet, but there are first innovations to build on.
Currently numerous manual handling steps in biopharmaceutical manufacturing come along with a high degree of failures in manufacturing facilities deriving from human errors in operative handling.
March 21, 2022
Katherine Spink has become member of Single Use Support’s Board of Directors. Her expertise in CGT consulting will enrich the companies’ focus on innovating solutions for advanced therapies.
March 17, 2022
Read more about CAR-T cell therapy, its history and hurdles. Learn also how Single Use Support can support this novel therapy with great potential!
March 17, 2022
Labs and manufacturers feel the pressure to deliver at a constantly accelerating pace while remaining flexible. In this article, you will learn how Single Use Support can bring you to the next level!
March 17, 2022
The National Health Service (NHS) of Great Britain, confirms the use of CAR-T Cell Therapy Kymriah on an 11-year-old leukaemia patient. However, it is not certain whether the vital therapy will make its way into society. Read it for yourself!
